Search

Search Results

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

  Galina Anatol’evna Gusarova, A.G. Turkina

  474-484

  01.10.2016

• Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

  K.M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I.S. Martynkevich, M.S. Fominykh, N.A. Potikhonova, I.I. Zotova, V.Yu. Udal’eva, R.A. Golovchenko, N.V. Shakhvorostova, D.I. Shikhbabaeva, M.N. Zenina, S.A. Tiranova, S.A. Kudryashova, L.S. Martynenko, M.P. Ivanova, N.Yu. Tsybakova, E.V. Petrova, L.B. Polushkina, E.V. Kleina

  54-60

  01.01.2016

• Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia

  N.S. Lazorko, Elza Galaktionovna Lomaia, E.G. Romanova, E.I. Sbityakova, E.R. Machyulaitene, P.A. Butylin, A.Yu. Zaritskii

  302-308

  01.07.2015

• First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

  Vasilii Anatol’evich Shuvaev, K.M. Abdulkadyrov, I.S. Martynkevich, M.S. Fominykh

  78–83

  01.01.2015

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014

• Cardiovascular complications of chronic myeloid leukemia treated with tyrosine kinase inhibitors

  G.E. Gendlin, L.M. Makeeva, E.I. Emelina, K.V. Shuikova, G.I. Storozhakov

  78-84

  01.01.2013